Spore powder of Ganoderma lucidum for the treatment of Alzheimer disease: A pilot study

BACKGROUND: This study explored the feasible efficacy and safety of the Spore Powder of Ganoderma Lucidum (SPGL) for treating patients with Alzheimer disease (AD). METHODS: Forty-two eligible patients with AD were recruited. These patients were randomly allocated to an intervention group and a contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Guo-hui, Wang, Li-hua, Wang, Chen, Qin, Li-hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959386/
https://www.ncbi.nlm.nih.gov/pubmed/29742702
http://dx.doi.org/10.1097/MD.0000000000010636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959386/
https://www.ncbi.nlm.nih.gov/pubmed/29742702
http://dx.doi.org/10.1097/MD.0000000000010636

Ejemplares similares